Pramiracetam

Pramiracetam
(IUPAC) ime
	N-[2-(diizopropilamino)etil]-2-(2-oksopirolidin-1-il)acetamid
Klinički podaci
Robne marke	Neupramir, Pramistar, Remen
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	68497-62-1
ATC kod	N06BX16
PubChem	51712
ChemSpider	46801
UNII	4449F8I3LE
ChEMBL	CHEMBL159776
Hemijski podaci
Formula	C14H27N3O2
Mol. masa	269,83 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18) ; Key: ZULJGOSFKWFVRX-UHFFFAOYSA-N
Farmakokinetički podaci
Poluvreme eliminacije	4,5 - 6,5 sata
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Unscheduled (US)
Način primene	Oralno

Pramiracetam je nootropni dijetarni suplement izveden iz piracetama. On je potentniji. Pramiracetam pripada racetamskoj familiji nootropika. Neka od trgovačkih imena su: Remen (Parke-Davis), Neupramir (Lusofarmaco) ili Pramistar (Firma).^[5]

Historija

Pramiracetam je razvila kompanija Parke-Davis tokom kasnih 1970-tih. Prvi patenti za ovaj lek su se pojavili 1978. (Belgija) i 1979. (SAD), uporedo sa prvim izveštajima o nootropinim karakteristikama.^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Axel Kleemann, Jürgen Engel, Bernd Kutscher und Dietmar Reichert: Pharmaceutical Substances, 4. Edition (2000). ISBN 978-1-58890-031-9.
↑ „Pramiracetam: Smarter Nootropics”. 30. 3. 2012.. Arhivirano iz originala na datum 2012-10-01. Pristupljeno 11. 4. 2012.

Vanjske veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[A._Kleemann-5] Axel Kleemann, Jürgen Engel, Bernd Kutscher und Dietmar Reichert: Pharmaceutical Substances, 4. Edition (2000). ISBN 978-1-58890-031-9.

[sn_pramiracetam-6] „Pramiracetam: Smarter Nootropics”. 30. 3. 2012.. Arhivirano iz originala na datum 2012-10-01. Pristupljeno 11. 4. 2012.

[1]

[2]

[3]

[4]

[5]

[6]